Interest in intervening prior to the onset of psychosis, in the prodromal or clinical high-risk (CHR) phase of illness, gained momentum in the 1990s. Initial treatment trials were conducted with the goal of preventing psychosis, but results to date have been equivocal. Only a few trials have found partial benefit of specific treatments over control conditions on transition rates, and even fewer show long-term gains. Challenges include high attrition and feasibility issues, especially for antipsychotic medication and cognitive remediation trials. While better tolerated, psychosocial therapy trials have mixed results, though when combined, meta-analyses show advantages compared to other treatments. Integrated treatment approaches lack specificity and the promising initial Omega-3 trial has not been replicated. Aside from conversion, early intervention appears to improve clinical outcomes including positive symptoms, depression, and anxiety. Importantly, treatment trials have not had a notable impact on functional outcomes, making this a crucial area for future research.